共 29 条
- [1] Klatersky J(2003)Side effects of ifosfamide Oncology 65 7-10
- [2] Rieger C(2004)Incidence and severity of ifosfamide-induced encephalopathy Anti-Cancer Drugs 15 347-350
- [3] Fiegl M(2007)Ifosfamide encephalopathy Clin Oncol 19 108-114
- [4] Tischer J(2007)Ifosfamide, gemcitabine, vinorelbine: a new induction regimen for refractory, relapsed Hodgkin’s lymphoma Haematologica 92 35-41
- [5] Ostermann H(2003)Pharmacology of Ifosfamide Oncology 65 2-6
- [6] Schiel X(2006)Methylene blue for management of ifosfamide-induced encephalopathy Ann Pharmacother 40 299-303
- [7] Ajithkumar T(2005)Evaluating risk factors for the development of ifosfamide encephalopathy Am J Clin Oncol 28 277-280
- [8] Parkinson C(2006)Role of thiamine in managing ifosfamide-induced encephalopathy J Oncol Pharm Pract 2 299-303
- [9] Shamshad F(2000)Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature Br J Cancer 82 291-294
- [10] Murray P(undefined)undefined undefined undefined undefined-undefined